Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients.

PHF6 mutations in adult acute myeloid leukemia. Leukemia (2010) 2.20

The role of CALM-AF10 gene fusion in acute leukemia. Leukemia (2007) 1.63

Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia (2012) 1.36

Identification of novel Myc target genes with a potential role in lymphomagenesis. Nucleic Acids Res (2004) 1.20

Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. Cancer Res (2007) 1.07

Mutations in the clathrin-assembly gene Picalm are responsible for the hematopoietic and iron metabolism abnormalities in fit1 mice. Proc Natl Acad Sci U S A (2003) 1.04

A modified "cross-talk" between histone H2B Lys-120 ubiquitination and H3 Lys-79 methylation. J Biol Chem (2010) 1.02

Endocytic proteins in the regulation of nuclear signaling, transcription and tumorigenesis. Mol Oncol (2009) 1.01

The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. Haematologica (2013) 0.96

Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. Blood (2009) 0.92

A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis. Blood (2013) 0.90

The radial nuclear positioning of genes correlates with features of megabase-sized chromatin domains. Chromosome Res (2012) 0.89

The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice. Oncogene (2011) 0.86

HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias. Oncogene (2013) 0.83

AF10 plays a key role in the survival of uncommitted hematopoietic cells. PLoS One (2012) 0.81

An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica (2016) 0.80

Nuclear export signal within CALM is necessary for CALM-AF10-induced leukemia. Cancer Sci (2014) 0.79

A critical role for CRM1 in regulating HOXA gene transcription in CALM-AF10 leukemias. Leukemia (2014) 0.79

Up a lymphoid blind alley: Does CALM/AF10 disturb Ikaros during leukemogenesis? World J Biol Chem (2011) 0.78

The Biochemical Properties and Functions of CALM and AP180 in Clathrin Mediated Endocytosis. Membranes (Basel) (2014) 0.78

FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia. Blood Cancer J (2011) 0.77

Modulation of PICALM Levels Perturbs Cellular Cholesterol Homeostasis. PLoS One (2015) 0.76

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43

A physical map of the human genome. Nature (2001) 12.39

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet (2001) 4.79

Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia (1995) 4.04

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet (1996) 3.75

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med (2001) 3.47

Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46

Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet (2000) 3.42

Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A (1991) 3.27

Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood (2000) 3.13

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78

The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood (2001) 2.77

TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene (1991) 2.71

Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 2.48

Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet (1991) 2.33

Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem (1992) 2.31

Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med (1993) 2.23

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia (2000) 2.21

Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11

Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Ann Hematol (1996) 2.05

MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A (1997) 2.01

Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia (1996) 1.96

Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet (1999) 1.96

Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood (2000) 1.93

Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia (2000) 1.91

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia (2004) 1.90

The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia. Proc Natl Acad Sci U S A (2001) 1.82

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia (2004) 1.77

Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood (1999) 1.75

Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood (1989) 1.74

An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet (2000) 1.73

Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol (1995) 1.72

Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura. Br J Haematol (1997) 1.71

All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood (1997) 1.71

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68

Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood (1995) 1.64

High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood (1989) 1.64

Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. Leukemia (2008) 1.62

Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia (2004) 1.59

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood (1999) 1.56

unc-3, a gene required for axonal guidance in Caenorhabditis elegans, encodes a member of the O/E family of transcription factors. Development (1998) 1.54

Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer (2001) 1.53

A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones (2001) 1.52

Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep (1982) 1.51

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia (2000) 1.51

[Ethics in medicine: needs and forms]. Internist (Berl) (1999) 1.51

Hodgkin's disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol (1981) 1.50

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48

Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol (1997) 1.46

A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol (2002) 1.44

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia (2007) 1.43

New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br J Haematol (1997) 1.43

Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia (2008) 1.43

Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet (1984) 1.42

Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 1.41

[Paraneoplastic syndromes]. Internist (Berl) (1994) 1.40

Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. Blood (1996) 1.40

Correlation of chromosomal aberrations in a myeloma cell line with tumorigenicity in nude mice. Blut (1981) 1.40

Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ (2006) 1.39

Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL. Leukemia (2005) 1.39

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia (2011) 1.38

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia (2005) 1.38

Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol (2003) 1.36

Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood (2001) 1.36

A maternal hypomethylation syndrome presenting as transient neonatal diabetes mellitus. Hum Genet (2006) 1.35

Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia (2002) 1.35

Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia (2008) 1.35

Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene (2007) 1.35

High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. J Med Genet (2007) 1.34

Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer (2001) 1.32

The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol (1994) 1.32

New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia (2005) 1.32

Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones (2000) 1.28

Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26

Management of acute myeloid leukemia in elderly patients. J Clin Oncol (1999) 1.25

Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol (2001) 1.25

High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia (2005) 1.24

Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood (2000) 1.24